Media Library
-
ImagelockLocations / ImageView from “Hohlweg” passing under the Novartis PavillonView from “Hohlweg” passing under the Novartis Pavillon
-
ImagelockLocations / ImageView of the Novartis Pavillon towards Dreirosenbrücke and city centerView of the Novartis Pavillon towards Dreirosenbrücke and city center
-
ImagelockLocations / ImageView from Kleinbasel towards Novartis Campus BaselView from Kleinbasel towards Novartis Campus Basel
-
ImagelockLocations / ImageBird's eye view, Novartis PavillonBird's eye view, Novartis Pavillon
-
ImagelockLocations / ImageMain entrance, Novartis PavillonMain entrance, Novartis Pavillon
-
ImagelockLeadership / ImageJohn D. YoungMember of the Board of Directors since March 7, 2023
-
PDFlockPublications / ReportNovartis in Society Integrierter Geschäftsbericht 2022The Novartis in Society Integrated Report covers our business, strategy and performance. It highlights progress against our ESG targets and describes how we create value for diverse stakeholders. This is the German version of the report.
-
ImagelockLocations / ImageManufacturing RNA therapies in Schweizerhalle, SwitzerlandManufacturing RNA therapies in Schweizerhalle, Switzerland
-
ImagelockLocations / ImageView of RNA production in Schweizerhalle, SwitzerlandView of RNA production in Schweizerhalle, Switzerland
-
ImagelockLocations / ImageProduction process of RNA therapies in Schweizerhalle, SwitzerlandProduction process of RNA therapies in Schweizerhalle, Switzerland
-
PDFlockFact Sheet52-week results for Cosentyx® in hidradenitis suppurativa: A summaryDiscover the data published in The Lancet on the long-term effect of Cosentyx® (secukinumab) in adults with hidradenitis suppurativa from the SUNRISE and SUNSHINE trials.
-
PDFlockPublications / ReportNovartis in Society Integrated Report 2022The Novartis in Society Integrated Report covers our business, strategy and performance. It highlights progress against our ESG targets and describes how we create value for diverse stakeholders.